"id:ID","studyInvestigationalInterventions","label","studyEstimands","studyDesignRationale","description","name","bcCategories","uuid","documentVersion","id"
"820","[]","","[]","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","Study Design 1","[]","9aa64caf-a84f-4ef3-a0ce-20d21675839f","","StudyDesign_1"
